3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Prostatic Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
5
Erectile Dysfunction
4
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Urinary Incontinence
1
Sexual Dysfunction, Physiological
1
Pyridoxine-dependent epilepsy
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurotoxicity Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Glioblastoma
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Astrocytoma
1
Abdominal Cancer
1
Interventions
Tea
2
Bupivacaine
2
Tadalafil
1
Morphine
1
Lidocaine
1
Ketamine
1
Injections, Subcutaneous
1
Influenza Vaccines
1
Ethanol
1
Dexmedetomidine
1
Anesthetics, Local
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Abdominal Cancer
×
Tadalafil
×
Clear all
NCT02998736
2022-12-28
PERIOP-04
Ottawa Hospital Research Institute
Phase 1
Completed
28 enrolled